| Literature DB >> 32963437 |
Geni Vg Soundaram1, Raja Sundaramurthy1, Kathiresan Jeyashree2, Vithiya Ganesan1, Ramesh Arunagiri1, Jhansi Charles1.
Abstract
INTRODUCTION: Implementation of evidence-based infection control practices is the need of the hour for every institute to reduce the device-associated infections, which directly reflects the quality of care. As catheter-associated urinary tract infection (CAUTI) is the most common nosocomial infection, the study was planned to evaluate the impact of the catheter care bundle in reducing CAUTI incidence.Entities:
Keywords: Care bundle; Catheter-associated urinary tract infection; Intensive care unit
Year: 2020 PMID: 32963437 PMCID: PMC7482344 DOI: 10.5005/jp-journals-10071-23473
Source DB: PubMed Journal: Indian J Crit Care Med ISSN: 0972-5229
Profile of patients admitted in adult ICUs of a tertiary care institute in Southern India pre- (April–June 2017) and post-implementation (October–December 2017) of urinary catheter care bundle (n = 1233)
| Age | 0.258 | ||
| ≤50 years | 341 (54) | 324 (53.8) | |
| 51–64 years | 220 (34.9) | 228 (37.9) | |
| 65–79 years | 65 (10.3) | 44 (7.3) | |
| ≥80 years | 5 (0.8) | 6 (1) | |
| Gender | 0.286 | ||
| Male | 430 (68.1) | 393 (65.3) | |
| Female | 201 (31.9) | 209 (34.7) | |
| Diagnostic condition | 0.534 | ||
| Neurological disease and procedure | 269 (42.6) | 257 (42.7) | |
| Pulmonary disease | 14 (2.2) | 5 (0.8) | |
| Cardiac disease and procedure | 190 (30.1) | 177 (29.4) | |
| GIT disease and procedure | 30 (4.8) | 4 (0.7) | 0.001 |
| Kidney disease and procedure | 45 (7.2) | 52 (8.6) | |
| Musculoskeletal disease | 41 (6.6) | 56 (9.3) | |
| Metabolic disease | 12 (1.9) | 6 (1) | |
| Other surgical procedure | 24 (3.9) | 40 (6.7) | |
| Poisoning | 4 (0.7) | 5 (0.8) | |
| Risk factors | |||
| Diabetic | 166 (26.3) | 151 (25.1) | 0.623 |
| Calculi | 14 (2.2) | 7 (1.2) | 0.225 |
| Stricture | 8 (1.3) | 2 (0.3) | 0.130 |
| Neurogenic bladder | 7 (1.1) | 2 (0.3) | 0.205 |
| Prostatic enlargement | 7 (1.1) | 1(0.1) | 0.088 |
ICU, intensive care unit
Analysis of nonadherence to each bundle care elements among adult ICUs of a tertiary care institute in Southern India, during pre-implementation (April–June 2017) of urinary catheter care bundle (n = 3003)—overall and ICU-wise
| Proper indication documented | 207/631 (32.8) | 34/91 (37.4) | 69/202 (34.2) | 81/170 (47.6) | 23/168 (13.7) |
| Closed drainage system | 366 (12.2) | 59 (12.2) | 87 (10.2) | 184 (16.7) | 36 (6.3) |
| Urinary catheter secured/not obstructed | 395 (13.2) | 72 (14.9) | 109 (12.8) | 162 (14.8) | 52 (9) |
| Drainage bag above floor and below bladder level | 183 (6.1) | 42 (8.7) | 45 (5.3) | 63 (5.7) | 33 (5.7) |
| Hand hygiene | 790 (26.3) | 158 (32.6) | 110 (13) | 423 (38.6) | 99 (17.2) |
| Vaginal/meatal care | 197 (6.6) | 38 (7.8) | 37 (4.4) | 73 (6.7) | 49 (8.5) |
| Perineal care | 889 (29.6) | 172 (35.5) | 224 (26.4) | 396 (36.1) | 97 (16.9) |
| Single-use glove while handling/emptying | 663 (22.1) | 102 (21.1) | 125 (14.7) | 367 (33.5) | 69 (12) |
| No contact b/t jug and bag | 270 (9) | 63 (13) | 61 (7.2) | 97 (8.9) | 49 (8.5) |
| Separate jug for collecting | 463 (15.4) | 88 (18.2) | 83 (9.8) | 247 (22.5) | 45 (7.8) |
| Assessment of readiness to remove—documented? | 1452 (48.4) | 226 (46.6) | 354 (41.2) | 723 (65.9) | 149 (26) |
Impact analysis of catheter care bundle among patients admitted in adult ICUs in a tertiary care institute in Southern India, during pre- (April–June 2017) and post-implementation (October–December 2017) of urinary catheter care bundle (n = 1,233)–overall and ICU wise
| Total no. of patients on urinary catheter | 631 | 602 | 91 | 94 | 202 | 147 | 170 | 190 | 168 | 171 |
| Total no. of catheter days[ | 3,003 | 2,225 | 484 | 388 | 849 | 564 | 1,096 | 868 | 574 | 405 |
| Total no. of patient days[ | 4,234 | 3,996 | 1,314 | 1,115 | 988 | 914 | 676 | 753 | 1,256 | 1,213 |
| Device utilization ratio (Poisson confidence interval)[ | 0.71 (0.684–0.735) | 0.56 (0.533–0.580) | 0.37 | 0.34 | 0.86 | 0.61 | 1.62 | 1.15 | 0.46 | 0.33 |
| Average catheter days per patient | 4.8 | 3.7 | 5.3 | 4.1 | 4.2 | 3.8 | 6.5 | 4.5 | 3.4 | 2.4 |
| No. of CAUTI | 32 | 10 | 5 | 2 | 8 | 2 | 16 | 5 | 3 | 1 |
| CAUTI incidence rate (Poisson confidence interval)[ | 10.7 (0.007–0.15) | 4.5 (0.002–0.008) | 10.3 | 5.1 | 10.6 | 3.5 | 14.6 | 5.7 | 5.2 | 2.4 |
Device utilization ratio: no. of indwelling catheter days/no. of patient days
Average catheter days per patient: No. of indwelling catheter days/no. of patients on catheter, p = 0.001
CAUTI incidence rate: no. of CAUTI/no. of indwelling catheter days × 1000
Catheter days—number of patients with indwelling urinary catheter collected daily at the same time and summed up for month for that specific location
Patient days—number of patients in the patient care collected daily at the same time and summed up for month for that specific location
Analysis of risk factor with CAUTI among patients admitted in adult ICUs in a tertiary care institute in Southern India, during pre- (April–June 2017) and post-implementation (October–December 2017) of urinary catheter care bundle (n = 1233)
| Diabetes | 166 | 25 (15.1) | 151 | 10 (6.62%) | 0.01 |
| Calculi | 14 | 4 (28.6) | 7 | – | |
| Stricture | 8 | – | 2 | – | |
| Neurogenic bladder | 7 | 1 (14.3) | 2 | – | |
| Prostatic enlargement | 7 | 79 (100) | 1 | – | |
Analysis of catheter days with CAUTI incidence among patients admitted in adult ICUs in a tertiary care institute in Southern India pre- (April–June 2017) and post-implementation (October–December 2017) of urinary catheter care bundle (n = 1,233)
| <5 | 359 (56.9) | 441 (73.3) | Nil | Nil | 0.001 |
| 5–10 | 258 (40.9) | 158 (26.2) | 20 (7.8) | 8 (5.1) | |
| >10 | 14 (2.2) | 3 (0.5) | 12 (85.7) | 2 (66.6) | |
Profile of patients with CAUTI admitted in adult ICUs of a tertiary care institute in Southern India before (April–June 2017) and after (October–December 2017) implementation of urinary catheter care bundle (n = 42)
| Age | ||
| ≤50 years | 7 (21.9) | – |
| 51–64 years | 9 (28.1) | 3 (30) |
| 65–79 years | 14 (43.7) | 7 (70) |
| >80 years | 2 (6.3) | – |
| Gender | ||
| Male | 19 (59.3) | 7 (70) |
| Female | 13 (40.7) | 3 (30) |
| Diagnostic condition | ||
| Neurological disease and procedure | 15 (46.9) | 2 (20) |
| Pulmonary disease | – | 2 (20) |
| Cardiac disease and procedure | 2 (6.3) | 1 (10) |
| GIT disease and procedure | – | 1(10) |
| Kidney disease and procedure | 8 (25) | 3 (30) |
| Musculoskeletal disease | 5 (15.6) | – |
| Metabolic disease | 1 (3.1) | 1 (10) |
| Other surgical procedure | 1 (3.1) | – |
| Risk factors | ||
| Diabetic | 25 (78.1) | 10 (100) |
| Calculi | 4 (12.5) | – |
| Neurogenic bladder | 1 (3.1) | – |
| Prostatic enlargement | 7 (21.9) | – |
| Organism isolated | ||
| | 15 (46.9) | 4 (40) |
| | 6 (18.7) | 4 (40) |
| | 6 (18.7) | 1 (10) |
| | 3 (9.5) | – |
| | 2 (6.2) | 1 (10) |
Antibiotic sensitivity pattern analysis of CAUTI isolates among patients admitted in adult ICUs in a tertiary care institute in Southern India pre- (April–June 2017) and post-implementation (October–December 2017) of urinary catheter care bundle (n = 42)
| Antibiotic sensitivity pattern (%)—pre-implementation | ||||||||||||
| Uropathogen (no. of isolate) | CAZ | CTR | CPM | AK | GEN | COT | CIP | OF | NIT | PIT | IMP | CL |
| 6.6 | 6.6 | 6.6 | 46.6 | 20 | 46.6 | 0 | 0 | 86.6 | 46.6 | 60 | 100 | |
| 0 | – | 0 | 0 | 0 | – | 0 | 0 | – | 16.6 | 33.3 | 100 | |
| 0 | 0 | 0 | 66.6 | 33.3 | 33.3 | 0 | 0 | 50 | 16.6 | 33.3 | 100 | |
| 33.3 | 33.3 | 33.3 | 66.6 | 66.6 | 33.3 | 33.3 | 33.3 | 66.6 | 33.3 | 66.6 | 100 | |
| Antibiotic sensitivity pattern (%)—post-implementation | ||||||||||||
| Uropathogen (no. of isolate) | CAZ | CTR | CPM | AK | GEN | COT | CIP | OF | NIT | PIT | IMP | CL |
| 25 | 25 | 25 | 75 | 50 | 50 | 0 | 0 | 75 | 25 | 50 | 100 | |
| 0 | – | 0 | 25 | 25 | – | 0 | 0 | – | 25 | 75 | 100 | |
| 0 | 0 | 0 | 100 | 0 | 100 | 0 | 0 | 100 | 100 | 100 | 100 | |
CAZ, ceftazidime; CTR, ceftriaxone; CPM, cefepime; AK, amikacin; GEN, gentamicin; COT, cotrimoxazole; CIP, ciprofloxacin; OF, ofloxacin; NIT, nitrofurantoin; PIT, Piperacillin-Tazobactum; IMP, imipenem; CL, colistin